Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
暂无分享,去创建一个
D. Amadori | R. Stahel | S. Siena | C. Zielinski | G. Cartenì | C. Manegold | C. Visseren-Grul | Y. Liu | J. Blatter | Yu Liu | G. Garcia | Giacomo Cartenì | Christian Manegold | Salvatore Siena | Christoph C. Zielinski | Dino Amadori | Rolf A. Stahel | Yu Liu
[1] R. Labianca,et al. Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] K. Nackaerts,et al. Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] C. Obasaju,et al. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. , 2007, Lung cancer.
[4] M. Metintaş,et al. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. García-Carbonero,et al. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[6] C. Obasaju,et al. Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] A. Ceribelli,et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Obasaju,et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. , 2005, Clinical lung cancer.
[9] Robert M. White,et al. Pemetrexed in malignant pleural mesothelioma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] D. Christiani,et al. Epidemiology, biologic behavior, and natural history of mesothelioma. , 2004, Thoracic surgery clinics.
[11] Richard Pazdur,et al. FDA drug approval summaries: pemetrexed (Alimta). , 2004, The oncologist.
[12] Bertram Price,et al. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. , 2004, American journal of epidemiology.
[13] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Giaccone,et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). , 2003, European journal of cancer.
[15] Duc Thanh Le,et al. Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma , 2003, Cancer investigation.
[16] K. Geisinger,et al. Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.
[17] J. Shamash,et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Ducreux,et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.
[19] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[20] J. Herndon,et al. Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma , 1999, Cancer.
[21] J. Dempsey,et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. , 1999, Seminars in oncology.
[22] F Levi,et al. The European mesothelioma epidemic , 1999, British Journal of Cancer.
[23] A. Musk,et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Herndon,et al. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Herndon,et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Stenwig,et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. , 1992, British Journal of Cancer.
[27] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[28] K. Antman. Clinical presentation and natural history of benign and malignant mesothelioma. , 1981, Seminars in oncology.